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Micromolar concentrations of extracellular -NAD
(NADe) activate human granulocytes (superoxide and NO gen-
eration and chemotaxis) by triggering: (i) overproduction of
cAMP, (ii) activation of protein kinase A, (iii) stimulation of
ADP-ribosyl cyclase and overproduction of cyclic ADP-ribose
(cADPR), a universal Ca2 mobilizer, and (iv) influx of extracel-
lular Ca2. Here we demonstrate that exposure of granulocytes
to millimolar rather than to micromolar NADe generates both
inositol 1,4,5-trisphosphate (IP3) and cAMP, with a two-step
elevation of intracellular calcium levels ([Ca2]i): a rapid, IP3-
mediated Ca2 release, followed by a sustained influx of extra-
cellular Ca2 mediated by cADPR. Suramin, an inhibitor of P2Y
receptors, abrogated NADe-induced intracellular increases of
IP3, cAMP, cADPR, and [Ca2]i, suggesting a role for a P2Y
receptor coupled to both phospholipase C and adenylyl
cyclase. The P2Y11 receptor is the only known member of the
P2Y receptor subfamily coupled to both phospholipase C and
adenylyl cyclase. Therefore, we performed experiments on
hP2Y11-transfected 1321N1 astrocytoma cells: micromolar
NADe promoted a two-step elevation of the [Ca2]i due to
the enhanced intracellular production of IP3, cAMP, and
cADPR in 1321N1-hP2Y11 but not in untransfected 1321N1
cells. In human granulocytes NF157, a selective and potent
inhibitor of P2Y11, and the down-regulation of P2Y11 expres-
sion by short interference RNA prevented NADe-induced
intracellular increases of [Ca2]i and chemotaxis. These
results demonstrate that -NADe is an agonist of the P2Y11
purinoceptor and that P2Y11 is the endogenous receptor in
granulocytes mediating the sustained [Ca2]i increase
responsible for their functional activation.
Extracellular NAD (NADe)2 is known to increase intracel-
lular calcium concentrations ([Ca2]i) in different cell types
and by different mechanisms (1–8). In cells expressing the
ecto-ADP-ribosyl cyclase (ADPRC) CD38, e.g. in CD38-trans-
fected fibroblasts and HeLa cells, as well as in native astrocytes,
retinalMuller cells and osteoblasts, direct conversion of NAD
to the Ca2 mobilizer cyclic ADP-ribose (cADPR) (9) has been
implicated as the principal mechanism leading to increases in
[Ca2]i in response to NADe (1, 3–6). In murine T lympho-
cytes, NADe is the substrate of the ecto-enzyme mono-ADP-
ribosyltransferase, which ADP-ribosylates the purinoceptor
P2X7 or a P2X7-associated protein, leading to Ca2 influx, for-
mation of large pores, and cell death (7, 10, 11). In human
monocytes, NADe and ADPR trigger influx of extracellular
Ca2, but neither CD38 nor P2X7-induced pore formation are
involved (8).
Recently, we demonstrated that NADe behaves as a pro-
inflammatory cytokine targeting human polymorphonuclear
granulocytes (12). Exposure of granulocytes to micromolar
concentrations of NADe (either the naturally occurring  or
the  form) triggered the following cascade of causally related
events: (i) activation of adenylyl cyclase and a rapid increase of
intracellular cAMP levels, (ii) PKA-mediated stimulation of
ADPRC activity and elevation of intracellular cADPR levels,
and (iii) sustained [Ca2]i rise, due to influx of extracellular
Ca2 (12). Increases in [Ca2]i are known to be responsible for
activation of human granulocytes (13). Indeed, NADe-induced
[Ca2]i elevation triggered increased O2 and NO generation
and enhanced chemotaxis toward NADe. Therefore, the
results obtained with NADe-stimulated granulocytes (12) sup-
port a key role of cADPR in control of receptor-mediated che-
motaxis inmurine and human granulocytes, as previously dem-
onstrated both in vivo (14) and in vitro (15).
The rapid increase of [cAMP]i in granulocytes that follows
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unidentified receptor, which activates the signaling cascade
involving cADPR and increased [Ca2]i that eventually results
in enhanced respiratory burst and chemotaxis. In the present
study, we challenged granulocytes with millimolar NADe.
Under these conditions, we observed a qualitatively different
Ca2 response, i.e. a biphasic one, with an initial inositol
1,4,5-trisphosphate (IP3)-mediated peak of [Ca2]i caused by
release from intracellular stores, followed by sustained influx of
extracellular Ca2. Given that (i) NAD is a nucleotide and (ii)
NADe-induced intracellular increases of IP3, cAMP, cADPR,
and [Ca2]i were abrogated by suramin, a relatively non-selec-
tive inhibitor of P2Y receptors, we focused on the possibility
that the signaling activities promoted by NADe were the result
of activation of a G protein-coupled P2Y receptor. The signal-
ing properties of P2Y receptors characterized to date suggested
the P2Y11 receptor as a putative NAD receptor, because its
activation increases both IP3 and cAMP levels by virtue of its
dual coupling to Gq and Gs (16–18). Results obtained with
hP2Y11-transfected 1321N1 astrocytoma cells reveal that
-NAD is an agonist of the P2Y11 purinoceptor. In addition,
the use of NF157 (a recently synthesized, selective inhibitor of
P2Y11) and the down-regulation of P2Y11 expression by short
interfering RNA (siRNA) demonstrate that endogenous P2Y11
is responsible for the NADe-induced activation of human
granulocytes.
EXPERIMENTAL PROCEDURES
Materials—FLUO-3AM and FURA-2AM were obtained
from Calbiochem (Milan, Italy). The [3H]cAMP and [3H]IP3
assay systems and Ficoll-Paque Plus were purchased from
AmershamBiosciences. A5 peptide (sequence: H2N-SLLWLT-
CRPWEAM-OH) was obtained from New England Peptide,
Inc. (Gardner, MA). Dulbecco’s modified Eagle’s medium and
RPMI cell culture medium were purchased from Cambrex Bio
Science Milano (Bergamo, Italy). NF157 was synthesized as
described (19). All other chemicals were obtained from Sigma
(Milan, Italy).
High-performance Liquid Chromatography Analyses of Nucleo-
tides and Chromatographic Purification of - and -NAD—
High-performance liquid chromatography analyses of nucleo-
tides and purification of - and -NAD were performed as
described previously (12).
Isolation of Human Granulocytes—Buffy coats, prepared
from freshly drawn blood of healthy volunteers, were provided
by Galliera Hospital, Genova, Italy. Granulocytes were isolated
from the buffy coats as described before (12).
Cell Culture—Control and hP2Y11-transfected 1321N1
astrocytoma cell lines (17) were cultured in Dulbecco’s modi-
fied Eagle’s medium supplemented with fetal calf serum (10%),
penicillin (50 units/ml), and streptomycin (50 g/ml) in a
humidified 5% CO2 atmosphere at 37 °C.
Fluorometric Measurements of [Ca2]i—Freshly prepared
granulocytes (10  106/ml) were loaded with 10 M FLUO-
3AM for 45min at 25 °C in RPMImedium, washed withHanks’
balanced salt solution (HBSS, cat. no.H8264, Sigma), and resus-
pended in the same solution or in Ca2-free HBSS (cat. no.
H6648, Sigma) at 5  106 cells/ml. [Ca2]imeasurements were
performed in 96-well plates (106 cells/well), and fluorescence
(excitation, 485 nm; emission, 520 nm) was measured every 3 s
with a fluorescence plate reader (Fluostar Optima, BMG
Labtechnologies GmbH, Offenburg, Germany). The intensity
of emitted light was plotted as a function of time. For [Ca2]i
calibration, granulocytes were loaded with 10 M FURA-2AM
for 45 min at 25 °C in RPMI medium, and measurements were
performed as described in a previous study (12).
Control and hP2Y11-transfected 1321N1 cells were seeded in
96-well plates (2  104 cells/well). After 24 h, cells were loaded
with 10 M FLUO-3AM for 45 min at 25 °C in complete
medium (Dulbecco’s modified Eagle’s medium) and washed
once with 0.2 ml of HBSS. The indicated concentrations of
nucleotides in HBSS (0.1 ml) were then added, and [Ca2]i
measurements were performed using the fluorescence plate
reader, as described above.
Determination of Intracellular cADPR Levels—Granulocytes
(40  106/ml) were incubated for 0, 15, and 60 min at 25 °C in
the absence (control) or in the presence of 1 mM -NAD. At
each time point, a 500-l aliquot of the cell suspension was
withdrawn and centrifuged at 5,000 g for 15 s, and the result-
ing cell pellets were lysed at 4 °C with 500 l of 0.6 M perchloric
acid (PCA). After centrifugation to remove precipitated pro-
teins, the cADPR content was measured on the neutralized
PCA cell extracts by a highly sensitive enzymatic cycling assay
(20). cADPR levels were expressed as picomoles/106 cells.
Control and hP2Y11-transfected 1321N1 cells were seeded in
35  10-mm dishes (2.4  105 cells/dish). After 48 h, the
medium was removed and HBSS was added (0.6 ml). ATP or
-NAD was added: the incubation was stopped after 15 min
by removal of HBSS and addition of 300 l if ice-cold PCA (0.6
M), and cells were removed by scraping. Cell extracts were cen-
trifuged to remove precipitated proteins, and the cADPR con-
tent was measured on the neutralized cell extracts as described
above.
Determination of Intracellular cAMP Levels—Granulocytes
were suspended in HBSS or in Ca2-free HBSS (30  106/ml),
preincubated for 5min at 25 °C in thepresenceof the cAMPphos-
phodiesterase inhibitor 4-(3-butoxy-4-methoxybenzyl)imidazoli-
din-2-one (Ro20-1724, Sigma, cat. no. B8279) (10M), and then
challenged with vehicle or 1 mM - or -NAD. At different
times (0, 20, 40, 60, 150, and 300 s), a 300-l aliquot of the
suspension was withdrawn, and the reaction was stopped by
adding 20 l of 9 M PCA at 4 °C. PCAwas removed as described
(20). Intracellular cAMP levels (expressed as picomoles of cAMP/
106 cells)were determinedby radioimmunoassay according to the
manufacturer’s protocol.
Control and hP2Y11-transfected 1321N1 cells were seeded in
35 10mmdishes (5 105 cells/dish). After 24 h, themedium
was removed and HBSS was added (0.6 ml). Cells were then
challenged with ATP or - or -NAD, and at different times
the incubation mixtures were stopped by removal of HBSS and
addition of 200 l of ice-cold PCA (0.6 M). Cells were removed
by scraping, the cell extracts were centrifuged to remove the
proteins, and the cAMP levels in the neutralized cell extracts
were measured as described above.
Determination of Intracellular IP3 Levels—Granulocytes
were resuspended inHBSS (40 106/ml) and challengedwith 1
mM -NAD. Aliquots of the suspensions (500 l) were with-
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drawn at different times (0, 30, and 90 s), and the reaction was
stopped by adding 30 l of 9 M PCA at 4 °C. Following removal
of PCA (20), intracellular IP3 levels were determined by radio-
immunoassay. Results were expressed as picomoles of IP3/106
cells.
Control and hP2Y11-transfected 1321N1 cells were seeded in
35 10-mmdishes (5 105 cells/dish). After 24 h, themedium
was removed and HBSS was added (0.6 ml). Cells were chal-
lenged with ATP or - or -NAD, and at various times (0, 30,
90, and 900 s) HBSS was removed and 300 l of ice-cold PCA
(0.6 M) was added. The cells were scraped, the precipitated pro-
teinswere removed by centrifugation, and IP3 levelsweremeas-
ured on the supernatants of the neutralized cell extracts as
described above.
Assays of ADP-ribosyl Cyclase Activity—hP2Y11-transfected
1321N1 cells (4  106/ml) were incubated at 25 °C in the
absence (control) or in the presence of 0.1mM -NAD orATP
for 10 min. After addition of 1:500 protease inhibitor mixture
(Sigma, cat. no. P8340) and 1:100 phosphatase inhibitor mix-
ture (Sigma, cat. no. P2850), control and stimulated cells were
lysed by sonication in ice for 1 min at 3 watts (Heat-System
Ultrasonics, W380, New York). ADP-ribosyl cyclase activity
was measured at 37 °C on cell lysates by adding 0.4 mM
-NAD. Aliquots (100l) werewithdrawn at various times (0,
10, and 30 min), the reactions were stopped by addition of 220
l of 0.9 M PCA to each aliquot, and the cADPR concentrations
weremeasured by the enzymatic cycling assay (20). The protein
content in each sample was determined by a Bradford assay
(21).
siRNA Transfection—Transfection of human granulocytes
was performed using the Nucleofector System (Amaxa GmbH,
Cologne, Germany). Preliminary experiments were carried out
with pmaxGFP to select the cell concentration, the Nucleofec-
tor solution, and program yielding the highest percentage of
cell transfection, which wasmonitored bymeasuring GFP-pos-
itive cells. Moreover, viability of freshly isolated granulocytes
was estimated at 24, 48, and 72 h measuring propidium iodide-
positive cells by flow cytometry: the corresponding figures of
cells viability were 78%, 49 and 10%, respectively. Thus, the
following protocols were chosen as optimal. Freshly isolated
granulocytes (20  106 cells) were transfected without (con-
trol), or with 2 M duplex short interference RNA (siRNA) or
with 2 g of pmaxGFP, using the Cell Line Nucleofector Kit T
according to the manufacturer’s instructions (Nucleofector
program X-005). The control siRNA was obtained from
Ambion (Austin, TX, negative control #1 siRNA). The P2Y11-
targeting siRNA was obtained from Invitrogen (P2RY11-
HSS143212: 5-UAUGUCUGCAAAGCUCGGGCAGCGG-
3). Immediately after transfection, cells were resuspended in
2.5 ml of RPMI supplemented with fetal calf serum (10%), pen-
icillin (50 units/ml), and streptomycin (50 g/ml) and incu-
bated in a humidified 5% CO2 atmosphere at 37 °C for 24 h.
After 24 h, GFP-positive cells were evaluated by using FACS-
Canto flow cytometer (BD Biosciences), and data, expressed as
percentage of alive, propidium iodide-negative cells, were ana-
lyzed by using DIVA software.
Real-time PCR—Twenty-four hours after transfection, total
RNA was extracted from cells (2  106 cells) using the RNeasy
mini kit (Qiagen) according to the manufacturer’s instructions
and reverse transcribed into cDNA using the Superscript III
first strand synthesis system (Invitrogen). The cDNA was used
as template for real-time PCR analysis: reactions were performed
in an iCycler iQ5 real-time PCR detection system (Bio-Rad). The
human P2Y11-specific primers were designed by using Beacon
Designer 2.0 software (Bio-Rad), and their sequences were as fol-
lows: 5-CGTGAGCTGAGCCAATGATGTG-3 (forward) and
5-GGGTGGGAAAGGCGACTGC-3 (reverse). Each sample
was assayed in triplicate in a 25-l amplification reaction, contain-
ing 30 ng of cDNA, primers mixture (0.4 M each of sense and
antisense primers), and 12.5 l of 2 iQ SYBR Green Supermix
Sample (Bio-Rad). The amplification program included 40 cycles
of twosteps, eachcomprisingheating to95 °Candto60 °C, respec-
tively. Fluorescent products were detected at the last step of each
cycle. To verify the purity of the products, a melting curve was
produced after each run. Values were normalized to -actin
mRNAexpression. Statistical analysis of thequantitative real-time
PCRwas obtained using the iQ5Optical System Software version
1.0 (Bio-Rad) based on the 2Ctmethod, which calculated rela-
tive changes ingeneexpressionof the target (P2Y11)normalized to
-actin and relative to a calibrator (“control,” cells subjected to
electroporation in the absence of siRNA). Amplification efficien-
cies of target and reference genes were determined by generating
standard curves. Data are presented as means  S.D.
Chemotaxis—Twenty-four hours after transfection, a 300-l
aliquot of granulocytes from each condition was centrifuged at
5000  g for 10 s, and cells were resuspended at 7  106/ml in
chemotaxis buffer (HBSS, phosphate-buffered saline, and 5%
albumin, 39:16:1). Chemotaxis assays were performed using
96-well ChemoTx system microplates (Neuro Probe, Inc.,
Gaithersburg, MD) with a 3-m pore size polycarbonate filter.
- or -NAD (10 M) were diluted in chemotaxis buffer and
added in the bottomwells. Granulocytes (25l) were placed on
top of the filter and incubated for 60 min at 37 °C: the transmi-
grated cells were evaluated as previously described (12). The
results were expressed as chemotaxis index (CI): CI  number
of cells migrated toward chemoattractant/number of cells
migrated toward medium.
Statistical Analyses—All parameters were tested by paired t
test. p values 	0.05 were considered significant.
RESULTS
Millimolar NADe Induces Both Transient and Sustained
Ca2 Responses in HumanGranulocytes—Incubation of intact,
freshly isolated granulocytes with extracellular -NAD
(-NADe) concentrations ranging from1 to 100M resulted in
a slowly developing, sustained elevation of [Ca2]i (12). As
shown in Fig. 1 (A and B), a markedly different Ca2 response
was consistently observed upon incubating granulocytes with 1
mM -NADe. Under these conditions, an immediate and tran-
sient elevation of the [Ca2]i (from 40 6 to 105 9 nM, n 5)
was followed by a sustained increase (to 145  28 after 15 min
from the addition of the nucleotide, n  5).
When 1mM -NADe was added to granulocytes in the pres-
ence of 0.3 mM extracellular EGTA in Ca2-free HBSS, the
kinetics and the extent of the immediate [Ca2]i increase were
superimposable to those recorded in a Ca2-containing
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medium (Fig. 1C), indicating that the transient increase inCa2
levels arises from release from intracellular stores and not from
extracellular influx. By contrast, the sustained Ca2 elevation
triggered by millimolar -NADe was markedly decreased
(80%) in the presence of EGTA, demonstrating that influx of
extracellular Ca2 is responsible for the sustained Ca2 eleva-
tion at longer times (Fig. 1C), similar to what was observedwith
micromolar -NADe concentrations (12).
1 mM -NADe elicited the same two-step pattern of Ca2
response as -NADe (Fig. 1D). Moreover, no appreciable
quantitative differences were observed in the Ca2 responses
elicited by -NADe or -NADe.
Distinct Roles of IP3 and cADPR in Transient and Sustained
Ca2 Responses of Intact Granulocytes to NADe—Preincuba-
tion of intact granulocytes with themembrane-permeant phos-
pholipase C (PLC) inhibitor (U73122, 5 M) abolished the early
transient [Ca2]i elevation promoted by either -NADe (Fig.
2A), or -NADe (not shown), whereas the same concentration
of the inactive analog U73343 proved to be ineffective (Fig. 2A).
Conversely, the sustained increase in [Ca2]i observed with -
and -NADe was not affected by pretreatment of the granulo-
cytes with either U73122 or U73343. These findings demon-
strate that - and -NADe at 1 mM evoke a rapid Ca2 release
from IP3-responsive intracellular stores.
To confirm the role of cADPR in the long lasting Ca2
response induced by millimolar -NADe, as was previously
demonstrated with micromolar -NADe concentrations (12),
intact granulocytes were exposed to -NADe (1 mM) following
preincubation with either 8-Br-cADPR (100 M), a membrane-
permeant cADPR antagonist (22), or ryanodine at 50M, a con-
centration that inhibits Ca2 release from cADPR-responsive
stores (23). Although neither treatment affected the first, tran-
sient [Ca2]i increase, both 8-Br-cADPR and ryanodine signif-
icantly reduced (approximately by 80%) the sustained [Ca2]i
elevation (Fig. 2, B and C). These results demonstrate that the
sustained Ca2 increase triggered by 1 mM NADe is mediated
by cADPR, similarly to what was observed at micromolar dinu-
cleotide concentrations. This cADPR-dependent Ca2
increase is abrogated in the presence of extracellular EGTA
(Fig. 1).
Intracellular IP3 , cADPR, and cAMP Concentrations in
NADe-stimulated Granulocytes—Exposure of granulocytes to
1 mM -NADe promoted a rapid increase in IP3 levels. Follow-
ing a 60-s incubation with the dinucleotide, intracellular IP3
levels increased by 2-fold, from a basal (unstimulated) value
of 0.25  0.03 pmol/106 to 0.54  0.08 pmol/106 cells (n  3,
p 	 0.005, Fig. 3A). Micromolar (10–100) concentrations of
-NADe did not promote significant changes in IP3 levels (data
not shown). These data demonstrate the causal involvement of
IP3 generation in the initial, transient [Ca2]i increase in
response to millimolar -NADe (Fig. 2A).
To investigate changes in cADPR levels promoted by milli-
molar NADe, we used -NADe as an agonist (12), which
proved to be as effective as -NADe in triggering a pathway
leading to stimulation of intracellular cADPR synthesis from
-NADi (12). -NADe was used to avoid possible interfer-
ence of the measurement of intracellular cADPR levels by
extracellular cADPR generated from -NADe (12). After a
FIGURE 1. Kinetics of -NADe
- and -NADe
-induced [Ca2]i increase in
human granulocytes. Fluo-3AM-loaded (A) or FURA-2AM-loaded (B) granu-
locytes were treated at 25 °C with 100 M (open triangles) or 1 mM -NAD
(black squares). Fluo-3AM-loaded granulocytes were treated at 25 °C with: C, 1
mM -NAD in calcium buffer (HBSS, black squares) or in HBSS containing 0.3
mM EGTA (open squares); D, 1 mM -NAD in calcium buffer (HBSS, black
squares) or in HBSS containing 0.3 mM EGTA (open squares). [Ca2]i changes
were measured in parallel using a fluorescence plate reader (A, C, and D), or
with the system described in Ref. 12 for [Ca2]i calibration (B). Nucleotide was
added at 50 s in A and B and at 70 s in C and D. Representative traces are shown
(A and C, n  11; B, n  5; D, n  7); B, each point is the mean of three [Ca2]i
values, recorded every 9 s (S.D.  15% of the mean value).
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15-min exposure of granulocytes to 1 mM -NADe, cADPR
levels increased to 300  80% (n  12, p 	 0.001) over basal
levels (19.11  4.01 pmol/109 cells, Fig. 3B), in agreement with
the concentration-dependent effects observed at micromolar
NADe (12).
Stimulation of granulocyte ADPRC and the subsequent
increase of [cADPR]i promoted by micromolar NADe were
shown to be dependent on the increase of cAMP and resulting
PKA activation (12). Likewise, basal cAMP levels of human
granulocytes (1.63  0.35 pmol/106 cells, n  10) increased
immediately after cell stimulation with 1 mM -NADe, reach-
ing maximal values after 60 s (186  16% of basal values, Fig.
3C). A comparable increase of the [cAMP]i was observed in
-NADe-stimulated cells (data not shown). Therefore, incuba-
tion of human granulocytes with millimolar NADe resulted in
comparably similar time course in elevation of intracellular IP3
and cAMP levels (peaking at 60 s), whereas a longer time (15
min) was required for intracellular cADPR to reach a plateau.
Role of Purinergic Receptors in the NADe-induced Ca2
Responses of Intact Granulocytes—Recently, a role for puriner-
gic receptors in nucleotide-triggered Ca2 responses or Ca2-
FIGURE 2. Role of IP3 and cADPR in the -NADe
-induced [Ca2]i increase
in human granulocytes. A, Fluo-3AM-loaded granulocytes were preincu-
bated at 25 °C for 10 min in HBSS in the presence of 5 M U73122 (open
triangles) or U73343 (black squares). B and C, granulocytes were preincubated
for 50 min in HBSS (control, black squares), or in HBSS containing 100 M
8-Br-cADPR (open squares, B) or 50 M ryanodine (open triangles, C) and then
loaded for further 40 min with Fluo-3-AM. -NAD (1 mM) was then added,
and [Ca2]i was measured in parallel using a fluorescence plate reader, as
described under “Experimental Procedures.” Nucleotide was added at 40 s in
A–C. Representative traces are shown (n  3 for each condition).
FIGURE 3. Intracellular IP3, cADPR, and cAMP levels in NADe
-stimulated
human granulocytes. After addition of 1 mM -NAD to control, untreated
granulocytes (black squares), or to cells preincubated for 1 h with 100 M
suramin (open squares), IP3 (A), cADPR (B), and cAMP (C) levels were deter-
mined at the times indicated, as described under “Experimental Procedures.”
Results are the mean  S.D. of at least three different experiments for each
assay.
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regulated cell functions in blood cells (24), dendritic cells (25),
and T lymphocytes (7, 10, 11) has emerged. To address the type
of receptors that mediate the NADe-induced Ca2 responses
in human granulocytes, intact cells were preincubatedwith sur-
amin, a widely used antagonist of both G protein-coupled P2Y
and ion channel-forming P2X receptors (24, 26). To investigate
the specificity of suramin as a P2Y receptor inhibitor in our cell
system, granulocytes were first incubated in the presence of
suramin (100M for 1 h) and then incubatedwith either 100M
ATP, 1 M fMLP, or 1 M A5 peptide (15). Indeed, suramin
strongly inhibited (87%,n 3) theATP-inducedCa2 increase,
whereas little to no changes in the P2Y-unrelated Ca2
responses to fMLP and A5 peptide were observed (15 and 0%
inhibition, respectively, n  3, data not shown).
Preincubation of human granulocytes with suramin resulted
in complete abrogation of the rapid, transient NADe-pro-
moted increase in intracellular Ca2 (Fig. 4). This finding,
together with the complete inhibition afforded by the PLC
inhibitor U73122 (Fig. 2A), suggested that the transient
increase of [Ca2]i promoted by millimolar NADe was due to
engagement of a PLC-coupled P2Y receptor. Consistent with
this hypothesis, suramin strongly inhibited NADe-promoted
increases in IP3 levels (Fig. 3A).
Interestingly, the slow, sustained elevation of [Ca2]i elicited
by 1 mM -NADe was also strongly inhibited (80  5%) by
suramin (Fig. 4). Thus, we explored the effect of suramin on
cAMP levels in granulocytes stimulated with 1 mM -NADe.
Indeed, preincubation with suramin resulted in complete inhi-
bition of cAMPgeneration (Fig. 3C). Likewise, preincubation of
granulocytes with suramin resulted in almost complete inhibi-
tion ofNADe-promoted increases in cADPR (Fig. 3B), suggest-
ing that a suramin-inhibitable receptor, triggered by 1 mM
NADe, lies upstream of the activation of AC and of ADPRC.
Taken together, these data demonstrate that in human granu-
locytes a suramin-inhibitable purinoceptor mediates both the
rapid, transient, and IP3-dependent elevation of [Ca2]i and the
subsequent slow, sustained cAMP/PKA/cADPR-dependent
elevation of [Ca2]i promoted by millimolar NADe.
Extracellular NAD Increases the [Ca2]i of P2Y11-1321N1
AstrocytomaCells—Among the humanG protein-coupled P2Y
receptor (hP2Y) subtypes cloned to date, only the hP2Y11
receptor couples to both PLC and adenylyl cyclase (16). To
establish whether the P2Y11 receptor is activated by NADe, we
investigated the effect of the dinucleotide on [Ca2]i in 1321N1
human astrocytoma cells stably expressing the hP2Y11 receptor
(1321N1-hP2Y11 cells) (17). To rule out possible interferences
afforded by metabolic by-products of NADe (e.g.ADPR, AMP,
and adenosine), we investigated the stability of- and-NADe
during incubation with both native 1321N1 and 1321N1-
hP2Y11 cells. Importantly, no significant degradation of either
dinucleotide form (100 M) was observed over 60 min at 25 °C.
Addition of 100 M -NADe to 1321N1-hP2Y11 cells pro-
moted a rapid and transient increase of [Ca2]i, followed by a
slow, sustained [Ca2]i rise. Conversely, -NADe did not
induce any Ca2 response on control 1321N1 cells (Fig. 5A),
indicating that the P2Y11 receptor was responsible for the
NADe-promoted transient and sustained increases of [Ca2].
In agreement with results obtained with human granulocytes,
the rapid and transient NADe-promoted elevation in [Ca2]i
was due to release from intracellular stores, because it was not
abrogated in the presence of extracellular EGTA. In contrast,
the sustained [Ca2]i rise elicited by NADe was completely
inhibited by extracellular EGTA, implicating Ca2 influx (data
not shown). Ca2 mobilization was also observed in 1321N1-
hP2Y11 cells challenged with extracellular ATP. The kinetics of
the Ca2 response was similar to those observed with NADe,
although consistently more robust (Fig. 5A).
Preincubation of 1321N1-hP2Y11 cells with either the PLC
inhibitor, U73122, or with suramin completely abrogated the
rapid and transient increase in [Ca2]i (Fig. 5, B and C), con-
firming the involvement of the PLC-coupled P2Y11 receptor in
triggering the rapid [Ca2]i rise. Suramin also abrogated the
slow and sustained [Ca2]i elevation, whereas the PLC inhibi-
tor was ineffective (Fig. 5, B and C). These results indicate that
the sustained [Ca2]i rise is also triggered by the P2Y11 recep-
tor, yet via a PLC-independent pathway. The sustained Ca2
increase, which was due to extracellular Ca2 influx, was inhib-
ited by preincubation of 1321N1-hP2Y11 cells with 8-Br-
cADPR (Fig. 5D), in agreement with previous data obtained for
human granulocytes (12).
Challenging 1321N1-hP2Y11 cells with ATP (100 M)
instead of NAD had no effect on the action of the various
inhibitors on the biphasic Ca2 response. Thus, suramin inhib-
ited almost completely (80  5%, n  3) both the rapid and
sustained increases in [Ca2]i, whereas U73122 abrogated only
the rapid, transient phase (n  3) and 8-Br-cADPR strongly
reduced (73  8%, n  3) only the slowly developing sustained
phase ofATP-promoted [Ca2]i increase (data not shown). The
sustained [Ca2]i increases induced by both -NADe (100M)
and ATP (100 M) in 1321N1-hP2Y11 cells were completely
inhibited by SKF96365 (10M, 1-min preincubation), an inhib-
itor of store-operated calcium channels (27).
Extracellular NAD Increases Intracellular IP3 , cAMP, and
cADPR Levels in 1321N1-hP2Y11 Cells—The results described
above clearly indicate the activation by -NADe of an IP3- and
a cAMP/cADPR-dependent pathway leading to discrete Ca2
responses in hP2Y11-1321N1 cells. The hP2Y11 receptor
expressed by 1321N1 cells is indeed known to be coupled to
both PLC and AC (16).
FIGURE 4. Effect of suramin on the -NADe
-induced [Ca2]i increase in
human granulocytes. Control, untreated (black squares) or suramin-treated
(100 M for 1 h, open triangles) granulocytes were loaded with Fluo-3AM and
exposed to 1 mM -NAD at 25 °C. [Ca2]i changes were measured in parallel
using a fluorescence plate reader, as described under “Experimental Proce-
dures.” Nucleotide was added at 40 s. Representative traces are shown (n  5).
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To conclusively demonstrate the role of IP3, cAMP, and
cADPR in the [Ca2]i responses triggered by NADe-induced
activation of P2Y11, we measured the intracellular concentra-
tions of these second messengers following NADe stimulation
of hP2Y11-1321N1 cells.
Challenge of 1321N1-hP2Y11 cells with 10 and 100 M
-NADe caused a steady elevation of IP3 levels, reaching 134
and 163% of basal values, respectively, recorded in unstimu-
lated cells (Table 1) andmeasured 30 s after addition of agonist.
By contrast, the same concentration of ATP induced a 3-fold
increase in IP3 levels in 1321N1-hP2Y11 cells. In native
1321N1 cells, the basal value of [IP3]i (8.79  1.32 pmol/106
cells) was not significantly modified by incubation with 100
M -NADe.
Because the hP2Y11 receptor is coupled to both Gq and Gs
(16), we determined whether NAD increased cAMP levels in
native 1321N1 and 1321N1-hP2Y11 cells. Following a 15-min
incubation with 100 M -NADe, cAMP levels increased from
a basal value of 2.53  0.45 pmol/106 cells to 10.11  1.06
pmol/106 cells (Table 1). Concentrations as low as 10 M
-NADe were capable of stimulating a significant increase in
cAMP (Table 1). In contrast to the effects induced by -NAD,
stimulation of 1321N1-hP2Y11 cells with 100 M ATP for 15
min resulted in a much greater increase in cAMP (to 196  41
pmol/106 cells, n  5). cAMP levels measured in control
1321N1 cells were not significantly increased in the presence of
100 M NAD.
We next investigated whether elevations in cAMP inNAD-
stimulated 1321N1-hP2Y11 cells are responsible for the slowly
developing, sustained [Ca2]i rise through the NADe-trig-
gered signaling pathway described in human granulocytes (12).
For this purpose, Fluo-3AM-loaded 1321N1-hP2Y11 cells were
incubated in the presence of the cell-permeant PKA activator,
8-Br-cAMP (500 M). As shown in Fig. 6, a sustained [Ca2]i
increase was recorded within 4 min of 8-Br-cAMP addition
(n  3), similar to that previously described in human granulo-
FIGURE 5. -NADe
- and ATP-induced [Ca2]i increase in hP2Y11-1321N1
cells. A, Fluo-3AM-loaded hP2Y11-1321N1 cells were treated with 100 M
-NADe
 (black squares) or with 100 M ATPe (open rhombus, inset); control
1321N1 cells were exposed to 100 M -NADe
 (open squares); B, untreated
(black squares) or U73122 preincubated (5 M for 10 min, open triangles)
hP2Y11-1321N1 cells were incubated with 100 M -NADe
; C, untreated
(black squares) or suramin preincubated (100 M for 1 h, open triangles)
hP2Y11-1321N1 cells were challenged with 100 M -NADe
; D, untreated
(black squares) or 8-Br-cADPR preincubated (100 M for 90 min, open triangles)
hP2Y11-1321N1 cells were incubated with 100 M -NADe
. [Ca2]i changes
were measured in parallel at 25 °C using a fluorescence plate reader, as
described under “Experimental Procedures.” Nucleotide was added at 70 s in
A–C and at 40 s in D. Representative traces are shown (A, n  8; B–D, n  5).
TABLE 1
-NADe
-induced intracellular IP3, cAMP, and cADPR increases in
hP2Y11-1321N1 cells
-NAD was added at the concentrations indicated to hP2Y11-1321N1 cells, IP3
levels were determined after 30 s from the addition of  -NADe (n  4), cAMP
levels were determined after 15 min from the addition of  -NADe (n  6), and
cADPR levels were measured in lysates from cells incubated for 15 min with
-NAD (n  5), as described under “Experimental Procedures.” Results are the
mean  S.D.
NADe IP3 cAMP cADPR
M pmol/106 cells
0 23.58  3.67 2.53  0.45 0.227  0.054
10 31.54  3.08a 3.70  0.41a 0.262  0.035
100 38.43  3.30b 10.11  1.06b 0.329  0.049a
a p 	 0.05.
b p 	 0.001.
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cytes (12). A comparable sustained [Ca2]i increase was also
obtained upon addition of 500 M 8-Br-cAMP to control
1321N1 cells (not shown).
The inhibition of the sustained increase in [Ca2]i afforded
by 8-Br-cADPR (Fig. 5D) prompted us tomeasure the effects of
NAD on both ADPRC activity (responsible for cADPR gener-
ation from -NAD) and on levels of cADPR in 1321N1-
hP2Y11 cells. Cells were incubated for 10min in the presence or
absence of 100 M -NADe (which is not a substrate of any
known ADPRC (28)), and levels of ADPRC activity were then
measured in cell lysates using -NAD as substrate. ADPRC
activity increased from 0.10  0.03 in unstimulated 1321N1-
hP2Y11 cells to 0.23  0.05 pmol of cADPR/min/mg of protein
in -NAD-treated cells (n  3, p 	 0.01). Conversely, no
increase of the ADPRC activity was recorded in P2Y11 cells
stimulated with -NADe (not shown).
Likewise, following a 15-min addition of 100 M -NADe to
1321N1-hP2Y11 cells, the levels of cADPR increased to 145 
22% of basal value (0.23  0.05 pmol/106 cells) (Table 1). Sim-
ilar results were obtained when 1321N1-hP2Y11 cells were
exposed for 15 min to 100 M ATP (increase to 0.33  0.08
pmol/106 cells, n  4). Conversely, cADPR levels in control
1321N1 cells (basal value, 0.22  0.05 pmol/106 cells, n  3)
were not significantly increased by 100 M -NADe.
Role of Endogenous P2Y11 in NAD-induced Activation of
HumanGranulocytes—Todemonstrate that endogenousP2Y11 is
the receptor responsible for the NAD-induced Ca2 response
leading to activation of human granulocytes, we followed two dif-
ferent experimental approaches. First, cells were preincubated
with 1 M NF157, a selective and potent P2Y11 receptor antago-
nist: as reportedbyUllmann et al. (19), 1MNF157doesnot affect
the P2Y2 purinoceptor, i.e. the receptor involved in the ATP-in-
duced activation of human granulocytes (29). Second, down-reg-
ulation of P2Y11 expression in human granulocytes was achieved
bymeans of specific siRNA transfection.
Preincubation of human granulocytes with NF157 resulted
in the abrogation of the sustained [Ca2]i increase induced by
100 M -NAD (not shown). Moreover, the presence of
NF157 completely prevented the transient [Ca2]i elevation
triggered by 1 mM -NAD and strongly inhibited (81  5%)
the sustained [Ca2]i increase induced by 1 mM -NAD (Fig.
7A). At the same time, the presence of NF157 abrogated the
NADe-promoted increases in IP3 and cAMP levels (Fig. 7, B
andC). Similar results were obtained upon stimulation of gran-
ulocytes with -NAD (not shown). In addition, as shown in
Fig. 7D, preincubation of cells with NF157 strongly inhibited
chemotaxis of human granulocytes toward 10 M - or
-NAD, the concentration triggering themaximal chemotac-
tic response (12).
Next, human granulocytes were transfected with specific
siRNA for P2Y11: after 24 h, P2Y11mRNA levels were decreased
to 20% compared with control cells (electroporated in the
absence of siRNA), as confirmed by real-time PCR analysis (Fig.
8A). The presence of a negative control siRNA did not induce
any significant modification of P2Y11 mRNA levels in human
granulocytes (Fig. 8A). The NADe-induced Ca2 responses
were then measured at 24 h after transfection: as shown in Fig.
8B, down-regulation of P2Y11 was accompanied by the almost
complete inhibition of both Ca2 responses triggered by 1 mM
-NAD, i.e. the IP3-related rapid increase and the cADPR-de-
pendent sustained rise. Comparable resultswere obtainedupon
stimulation of cells with 1 mM -NAD (not shown). Finally,
P2Y11 siRNA-transfected, negative control siRNA-transfected,
and control granulocytes were comparatively challenged to
migrate toward 10 M - or -NAD: as shown in Fig. 8C,
transfection with specific siRNA for P2Y11 completely pre-
vented chemotaxis of granulocytes.
DISCUSSION
The recent discovery of NAD as an extracellular agonist
eliciting functional activation of human granulocytes (12) high-
lighted a new mechanism for this dinucleotide, which was dis-
tinct from its action in other mammalian cell types (1–8). In
astrocytes, osteoblasts, CD38-transfected fibroblasts, andHeLa
cells, CD38, an ecto-ADPRC, converts NADe into the intracel-
lular calciummobilizer cADPR (1, 3, 5, 6). Subsequent translo-
cation of extracellularly generated cADPR into the cytoplasm,
where it can cause release of Ca2 stores by binding to the
ryanodine receptor, is performed either by CD38 itself or by
nucleoside transporters (1). InmurineT lymphocytes, the addi-
tion of NADe promotes Ca2 influx secondary to NADe-me-
diated ADP ribosylation of the P2X7 purinoceptor or of a P2X-
associated protein (7, 10, 11).
In contrast, the [Ca2]i increase in human granulocytes pro-
moted by micromolar NADe occurs through (i) overproduc-
tion of cAMP, (ii) activation of PKA, (iii) stimulation of ADPRC
activity and consequent overproduction of cADPR, and (iv)
influx of extracellular Ca2 (12). Functional equivalence
between -NADe and -NADe, which is not a substrate of
either ADPRCs (28) or ADP-ribosyl transferases (30), sug-
gested that NADe activates one or more plasma membrane
receptors coupled to a signaling pathway that result in granu-
locyte activation. However, identification of such receptor(s)
has remained elusive (12).
The results obtained in this study demonstrate for the first
time that NADe is an endogenous agonist of the P2Y11 purino-
ceptor and that engagement of P2Y11 by extracellular NAD
FIGURE 6. 8-Br-cAMP-induced [Ca2]i increase in hP2Y11-1321N1 cells.
Traces shown, representative of three different experiments, were obtained
upon addition (at 300 s) of 500 M 8-Br-cAMP (black squares) to Fluo-3AM-
loaded hP2Y11-1321N1 cells. Open triangles indicate the same cells without
addition of 8-Br-cAMP. [Ca2]i changes were measured in parallel at 25 °C
using a fluorescence plate reader.
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triggers a cADPR-dependent Ca2 signaling eventually leading
to activation of human granulocytes. Both conclusions are sup-
ported by several biochemical, pharmacological, andmolecular
lines of evidence. A first clue came from the finding of different
patterns of [Ca2]i variations induced by micromolar and mil-
limolar NADe concentrations. The two steps of Ca2 mobili-
FIGURE 7. Effect of NF157 on the NADe
-induced [Ca2]i, [IP3]i and [cAMP]i
increases and on NAD-directed chemotaxis in human granulocytes.
A, control, untreated (black squares) or NF157-treated (1 M for 1 h, open
triangles) granulocytes were loaded with Fluo-3AM and exposed to 1 mM
-NAD at 25 °C. [Ca2]i changes were measured in parallel using a fluores-
cence plate reader, as described under “Experimental Procedures.” Nucleo-
tide was added at 70 s. Representative traces are shown (n  3). After addition
of 1 mM -NAD to control, untreated granulocytes (black squares), or to cells
preincubated for 1 h with 1 M NF157 (open squares), both IP3 (B) and cAMP (C)
levels were determined at the times indicated, as described under “Experi-
mental Procedures.” Results are the mean  S.D. of at least three different exper-
iments for each assay. D, migration of granulocytes preincubated, or not
(control), with NF157 (1 M for 40 min) through 3-m pore membranes
toward a medium containing, or not, 10 M -NAD (black bars) or -NAD
(white bars), was measured in ChemoTx chambers and the chemotaxis index
(CI) was calculated. Migration of NF157-pretreated granulocytes toward the
medium in the absence of NAD was not significantly different from that of
control, untreated cells. Results shown are the mean  S.D. of four experi-
ments (p 	 0.005).
FIGURE 8. Effect of siRNA for P2Y11 on the NADe
-induced [Ca2]i
increases and NAD-directed chemotaxis in human granulocytes. 24 h
after transfection, control (electroporated in the absence of siRNA), negative
control siRNA-transfected, or P2Y11 siRNA-transfected granulocytes were
treated as follows. A, subjected to total RNA extraction: real-time PCR for
P2Y11 expression was performed as described under “Experimental Proce-
dures” (n  3); B, loaded with Fluo-3AM and exposed to 1 mM -NAD at 25 °C
(control, black squares; control siRNA, open triangles; P2Y11 siRNA, open
squares). [Ca2]i changes were measured in parallel using a fluorescence
plate reader, as described under “Experimental Procedures.” Nucleotide was
added at 70 s. Representative traces are shown (n  3); C, challenged to
migrate toward a medium containing, or not, 10 M -NAD (black bars) or
-NAD (white bars). Migration was measured in ChemoTx chambers, and the
chemotaxis index (CI) was calculated. Migration of transfected granulocytes
toward the medium in the absence of NAD was not significantly different
from that of control cells. Results shown are the mean  S.D. of three exper-
iments (p 	 0.001).
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zation proved to involve independent, not causally interrelated
mechanisms, because the fast, IP3-mediated increase in [Ca2]i
was not necessary to induce the subsequent sustained [Ca2]i
rise. These results indicated that the role of the cAMP/cADPR
pathway is predominant at micromolar NADe over the PLC/
IP3 cascade. Activation of both signaling pathways by millimo-
lar NADe concentrations suggested two alternative explana-
tions: (a) binding of high [NAD]e to two different plasma
membrane receptors, each of which couples to a distinct signal-
ing cascade and (b) interaction of NADe with a single receptor
coupling to both pathways of the Ca2 response.
NAD per se has never been demonstrated to be a ligand of
purinoceptors, although it bears structural similarity with the
classic agonists of purinoceptors, ADP and ATP. P2 (nucleo-
tide) receptors encompass the ion channel forming P2X recep-
tors and the G protein-coupled P2Y receptors. Whereas the
seven subtypes of P2X receptors (P2X1–7) are primarily acti-
vatedbyATP, the eight subtypesofP2Yreceptors (P2Y1,2,4,6,11–14)
are activated by a wider range of nucleotides and nucleotide
analogs (26).
The abrogation of all the -NAD-promoted effects by sur-
amin, a non-selective inhibitor of the family of P2 receptors (24,
26), suggested the possibility that NADe was an agonist at one
or more P2Y receptors; indeed, P2Y receptors are involved in
PLC and/or AC activation (26). Human granulocytes express
P2Y2, P2Y4, P2Y6, and P2Y11 receptor subtypes, as revealed by
reverse transcription-PCR analysis (29). P2Y2, P2Y4, and P2Y6
receptors are coupled to PLC, resulting in the formation of IP3
and mobilization of [Ca2]i, as well as activation of PKC (31).
Notably, distinct fromothermembers of the P2Y subfamily, the
human P2Y11 receptor is functionally coupled to both PLC and
AC (16).
The unambiguous association of any P2Y receptor subtype
with a specific physiological effect is hampered by the lack of
subtype-selective agonists and antagonists (17). Thus, the phar-
macological selectivities of these receptors can be optimally
defined by expressing individual subtypes of cloned P2Y recep-
tors in null cells. In our study, an astrocytoma cell line (1321N1)
expressing the human P2Y11 (17) was exploited to determine
the possible activation of this receptor byNADe. Indeed, native
1321N1 astrocytoma cells lack expression of any known P2
receptor subtypes (32). -NADe triggers both the cAMP/
cADPR and the PLC/IP3 pathways in 1321N1-hP2Y11 cells but
not in native 1321N1 cells.
The fact that the hP2Y11 receptor is the only purinoceptor
coupled to AC, together with its known expression in granulo-
cytes, implicated the hP2Y11 receptor as the putative receptor
responsive to NADe in these cells. This view received experi-
mental support by use of NF157, a suramin-related P2Y11-se-
lective antagonist, which was recently synthesized and charac-
terized (19). Indeed, 1 M NF157 abrogated in granulocytes
both Ca2 responses elicited by millimolar NADe (Fig. 7A).
Final evidence for the identification of P2Y11 as the NAD-
binding purinoceptor that mediates granulocyte activation was
provided by specific siRNA transfection (Fig. 8). A significant
decrease in P2Y11 mRNA levels, observed 24 h after transfec-
tion with specific siRNA, indicates a relatively high turnover of
P2Y11 in human granulocytes (Fig. 8A). The experiments with
P2Y11-specific siRNA unequivocally identified P2Y11 as the
receptor interacting with NADe.
Previous studies performed on 1321N1-hP2Y11 astrocytoma
cells provided information on the pharmacological properties
of this purinoceptor, demonstrating that it couples to AC and
PLC with different efficiencies depending on the used agonist
(16, 17). Specifically, previous data demonstrated that coupling
of P2Y11 with AC was triggered by ADP with a lower potency
than by ATP as an agonist (17), whereas UTP stimulation did
not lead to accumulation of IP3, under conditions inwhichATP
gave a robust effect (33).
From the standpoint of agonist activity, it is of potential bio-
logical interest that, like -NADe, micromolar ATPe also
evoked both an initial IP3-dependent Ca2 spike and a cADPR-
dependent sustained [Ca2]i rise in 1321N1-hP2Y11 cells. The
ATP-promoted sustained rise in intracellular Ca2 was signif-
icantly higher than that evoked by -NADe (Fig. 5A); this dif-
ference might be accounted for by the greater depletion of
intracellular Ca2 stores elicited by ATP via IP3 overproduc-
tion (34), as suggested by experiments with SKF96365 (see
“Results”). cADPR was involved in the slowly developing sus-
tained rise in [Ca2]i promoted by both -NADe and ATPe, as
demonstrated by the substantial inhibition afforded by 8-Br-
cADPR. Previous reports have postulated the occurrence of a
cADPR-mediated activation of store-operated calcium
channels (12, 14, 35–38). In recent years, growing evidence
has accumulated that strongly implicates the TRPM2 chan-
nels as responsible for cADPR- and ADPR-mediated Ca2
influx (39, 40).
The causal role of cADPR in the sustained [Ca2]i rise
induced by both NADe and ATPe in the hP2Y11-132N1 cells is
well established. However, it is somewhat surprising that the
increase of intracellular cADPR in the hP2Y11 cells was not
much greater with ATP than with NADe (see “Results”). This
seems to contrast with the different extents of [cAMP]i eleva-
tion in response to -NADe and ATPe, respectively, with ATP
being far more potent and efficacious in stimulating cAMP
overproduction. A possible explanation for this quantitative
discrepancy might be the attainment of near-maximal activa-
tion of PKA at the [cAMP]i levels induced by -NADe.
In conclusion, the present study demonstrates that -NADe
is an endogenous agonist of the P2Y11 purinergic receptor, act-
ing as a pro-inflammatory cytokine on human granulocytes. In
this respect, increased levels of NADe and ATP expected at
sites of inflammation, as a consequence of cell lysis (11) or of
regulated release (41, 42), are likely to be sufficient to trigger
functional responses in granulocytes, particularly enhanced
chemotaxis, that are causally related to the cADPR/Ca2 sys-
tem (12). Specifically, as far as NADe concentrations are con-
cerned, these average 50–100 nM in human blood plasma (1),
thus close to those resulting in enhanced chemotaxis (12). In
vivo, the extent of cell lysis as a source of NADe at specific sites
can only be postulated, but hardly estimated. Conversely, the
established capacity of increased [Ca2]i of down-regulating
intracellularNAD release via PKC-mediated phosphorylation
of Cx43 hemichannels (43) might suggest the opposite process,
i.e. opening of these hemichannels via dephosphorylation and
consequently enhanced efflux of NAD from cells.
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